Ray Dalio Repligen Corp Transaction History

Bridgewater Associates, LP

  • $17.3 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
BUY
$162.42 - $220.56 $759,151 - $1.03 Million
4,674 Added 210.16%
6,898 $1.17 Million
Q3 2022

Nov 10, 2022
SELL
$160.42 - $256.21 $222,342 - $355,107
-1,386 Reduced 38.39%
2,224 $416,000
Q2 2022

Aug 11, 2022
BUY
$140.68 - $188.02 $86,940 - $116,196
618 Added 20.66%
3,610 $586,000
Q1 2022

May 13, 2022
BUY
$161.19 - $257.96 $482,280 - $771,816
2,992 New
2,992 $563,000
Q4 2021

Feb 14, 2022
SELL
$247.59 - $304.47 $182,226 - $224,089
-736 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$194.77 - $324.21 $143,350 - $238,618
736 New
736 $213,000

Others Institutions Holding RGEN

# of Institutions
488
Shares Held
54.2M
Call Options Held
341K
Put Options Held
235K
View Full List

About REPLIGEN CORP

RGEN Quotes by TradingView
  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $7.98B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email